Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
RECONNECT-S GAMMA : A Non-interventional Study to Observe Real-life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
In this NIS subject's data will be collected at one visit at the moment of discharge from the hospital.
The results of the study would help to characterise the discrepancy between current clinical practice and treatment guidelines, indicating that atypical antipsychotics are preferable and should be used in monotherapy during acute psychotic episodes in subjects with schizophrenia. Available evidence have revealed a frequent use of first-generation antipsychotics, polypharmacy, intramuscular route of administration and use of atypical antipsychotics in doses lower than recommended in registered summary of product characteristics.
調査の概要
状態
条件
詳細な説明
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Budapest、ハンガリー
- Research Site
-
Debrecen、ハンガリー
- Research Site
-
Gyor、ハンガリー
- Research Site
-
Kerepestarcsa、ハンガリー
- Research Site
-
Nyiregyhaza、ハンガリー
- Research Site
-
Szekesfehervar、ハンガリー
- Research Site
-
Szekszard、ハンガリー
- Research Site
-
-
-
-
-
Daugavpils、ラトビア
- Research Site
-
Jelgava、ラトビア
- Research Site
-
Liepaja、ラトビア
- Research Site
-
Riga、ラトビア
- Research Site
-
Strenci、ラトビア
- Research Site
-
-
-
-
-
Bucharest、ルーマニア
- Research Site
-
Iasi、ルーマニア
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Written Informed Consent has been obtained from the Subject and/or his/her legal representative (as per local regulatory requirements).
- Meet the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria
- Subject is hospitalised due to an acute psychotic episode
Exclusion Criteria:
- Current participation in any clinical trial.
- Previous enrolment in the present NIS (in case of recurrence occurred during the enrolment period)
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Acute psychotic episode in schizophrenia
Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Description of used atypical antipsychotic(s) during hospitalisation
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
The data will be collected at one visit at the moment of discharge from the hospital.
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of the daily dosage of atypical antipsychotic(s) during hospitalisation
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
The data will be collected at one visit at the moment of discharge from the hospital.
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of mode of administration of atypical antipsychotic(s) during hospitalisation
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
The data will be collected at one visit at the moment of discharge from the hospital.
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Percent of patients with atypical antipsychotic as monotherapy
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Percent of patients with combinations of antipsychotics.
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of main criteria used for selection of an antipsychotic during hospitalisation.
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of the usage of psychometric scales in day to day practice, to evaluate the disease symptoms and thus the efficacy of treatment.
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of used concomitant psychiatric medication (other than atypical antipsychotic) during the hospitalization
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of the relationship between medication used during the hospitalization and maintenance therapy recommended upon discharge
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
Description of the study population by collecting the following exploratory variables: demographic, educational, economical, social data, psychiatric and somatic health.
時間枠:hospitalisation period, an expected average of 2 weeks (variable per patient)
|
hospitalisation period, an expected average of 2 weeks (variable per patient)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Radu TEODORESCU, Prof.、Spitalul Clinic of Psychiatry named after Prof. Dr. Alexandru Obregia, Romania
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- NIS-NME-SER-2011/1
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。